Home
Storia in 2 fonti
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.
- ·
cnbc.com
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.
- ·
cincodias.elpais.com
Novo Nordisk repunta en Bolsa tras la aprobación de EE UU para utilizar Wegovy en enfermedades hepáticas
La autorización de la Administración de Alimentos y Medicamentos (FDA) supone el segundo impulso para la compañía